6f1a6f45 personal page - To The Moon

6f1a6f45

No personal profile

70Follow

3Followers

0Topic

0Badge

2022-12-06

👍👍👍

2022-12-05

👍👍👍👍

2022-12-04

👍

2022-12-04

👍

2022-11-29

👍

Siludi applies to issue 16.35 million shares through Hong Kong IPO

2022-11-29

👍

Sorry, the original content has been removed

2022-11-29

👍

IPO News: 3D MEDICINES-B (01244.HK) launches its IPO today with an entry fee of HK$13,252.23 per lot.

2022-11-29

👍

[IPO] 3D MEDICINES-B (01244) begins its IPO today with an entry fee of HK$13,252.23.

2022-11-29

👍

IPO | 3D MEDICINES-B begins IPO today, admission fee HK$13,252.23

2022-11-22

Woow going cool🔥😀

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4130472326487360","uuid":"4130472326487360","gmtCreate":1667369439139,"gmtModify":1667369439139,"name":"6f1a6f45","pinyin":"6f1a6f45","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":1,"fanSize":3,"headSize":70,"tweetSize":12,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":629384276,"gmtCreate":1670270184797,"gmtModify":1676538332593,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍👍👍","listText":"👍👍👍","text":"👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/629384276","isVote":1,"tweetType":1,"viewCount":3675,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":629990197,"gmtCreate":1670182306121,"gmtModify":1676538314350,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍👍👍👍","listText":"👍👍👍👍","text":"👍👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/629990197","isVote":1,"tweetType":1,"viewCount":3554,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":629052879,"gmtCreate":1670121696592,"gmtModify":1676538306259,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/629052879","isVote":1,"tweetType":1,"viewCount":3842,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":629052153,"gmtCreate":1670121682274,"gmtModify":1676538306258,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/629052153","isVote":1,"tweetType":1,"viewCount":3640,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620879931,"gmtCreate":1669691002724,"gmtModify":1676538224047,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/620879931","repostId":"2287354144","repostType":2,"repost":{"id":"2287354144","kind":"news","pubTimestamp":1669674367,"share":"https://ttm.financial/m/news/2287354144?lang=en_US&edition=fundamental","pubTime":"2022-11-29 06:26","market":"hk","language":"zh","title":"Siludi applies to issue 16.35 million shares through Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2287354144","media":"媒体滚动","summary":"思路迪（3D Medicines）在港交所公告称，申请通过香港IPO发行1635万股股票，股票发行价指导区间为每股22.96-26.24港元，预计12月15日将开始交易。","content":"<p><html><body>3D Medicines announced on the Hong Kong Stock Exchange that it has applied to issue 16.35 million shares through a Hong Kong IPO, with a guidance price range of HK$22.96-26.24 per share. Trading is expected to begin on December 15.</p><p></body></html></p>","source":"sina_symbol","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Siludi applies to issue 16.35 million shares through Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSiludi applies to issue 16.35 million shares through Hong Kong IPO\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">媒体滚动</strong><span class=\"h-time small\">2022-11-29 06:26</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body>3D Medicines announced on the Hong Kong Stock Exchange that it has applied to issue 16.35 million shares through a Hong Kong IPO, with a guidance price range of HK$22.96-26.24 per share. Trading is expected to begin on December 15.</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-11-29/doc-imqmmthc6355254.shtml\">媒体滚动</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01244":"思路迪医药股份","IPO":"Renaissance IPO ETF"},"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-11-29/doc-imqmmthc6355254.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2287354144","content_text":"思路迪（3D Medicines）在港交所公告称，申请通过香港IPO发行1635万股股票，股票发行价指导区间为每股22.96-26.24港元，预计12月15日将开始交易。","news_type":1,"symbols_score_info":{"IPO":1,"01244":1}},"isVote":1,"tweetType":1,"viewCount":4207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620870264,"gmtCreate":1669690966159,"gmtModify":1676538224024,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/620870264","repostId":"2287453885","repostType":2,"isVote":1,"tweetType":1,"viewCount":4320,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620870130,"gmtCreate":1669690916322,"gmtModify":1676538224016,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/620870130","repostId":"2287545465","repostType":2,"repost":{"id":"2287545465","kind":"news","pubTimestamp":1669681671,"share":"https://ttm.financial/m/news/2287545465?lang=en_US&edition=fundamental","pubTime":"2022-11-29 08:27","market":"us","language":"zh","title":"IPO News: 3D MEDICINES-B (01244.HK) launches its IPO today with an entry fee of HK$13,252.23 per lot.","url":"https://stock-news.laohu8.com/highlight/detail?id=2287545465","media":"AAFN","summary":"生物医药公司3D MEDICINES-B公布招股详情，拟全球发售1,635万股，香港公开发售占一成，国际发售占九成。招股价介乎每股22.96至26.24元。每手500股计，一手入场费13,252.23元。该股今日起招股，下周三中午截止，预期将于12月15日挂牌。公司上市引入4名基石投资者，包括徐州经开区(香港)、Harvest、TradArt Investment SP及Mobilewise，合共认购2.35亿元公司股份。","content":"<p><div>Biopharmaceutical company 3D MEDICINES-B (01244.HK) announced details of its IPO, planning to offer 16.35 million shares globally, with 10% from the Hong Kong public offering and 90% from the international offering. The offer price ranged from RMB22.96 to RMB26.24 per share. Each lot consists of 500 shares, and the entry fee for each lot is 13,252.23 yuan. The stock begins its IPO today (November 29) and closes at noon next Wednesday (December 7). It is expected to be listed on December 15. The joint sponsors are CICC and CITIC Securities International. The company's IPO attracted four cornerstone investors, including Xuzhou Economic and Technological Development Zone (Hong Kong), ...</p><p><a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1229684&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web page link</a></div></p>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO News: 3D MEDICINES-B (01244.HK) launches its IPO today with an entry fee of HK$13,252.23 per lot.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO News: 3D MEDICINES-B (01244.HK) launches its IPO today with an entry fee of HK$13,252.23 per lot.\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">AAFN</strong><span class=\"h-time small\">2022-11-29 08:27</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div>Biopharmaceutical company 3D MEDICINES-B (01244.HK) announced details of its IPO, planning to offer 16.35 million shares globally, with 10% from the Hong Kong public offering and 90% from the international offering. The offer price ranged from RMB22.96 to RMB26.24 per share. Each lot consists of 500 shares, and the entry fee for each lot is 13,252.23 yuan. The stock begins its IPO today (November 29) and closes at noon next Wednesday (December 7). It is expected to be listed on December 15. The joint sponsors are CICC and CITIC Securities International. The company's IPO attracted four cornerstone investors, including Xuzhou Economic and Technological Development Zone (Hong Kong), ...</p><p><a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1229684&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web page link</a></div></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1229684&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">AAFN</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","BK1521":"挪威政府全球养老基金持仓","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0577902538.SGD":"Fullerton Lux Funds - Asia Growth and Income Equities A Acc SGD","LU0873338254.USD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (USD) INC","00388":"香港交易所","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","BK1589":"北水核心资产","LU0577902454.USD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (USD) ACC","LU0577902371.SGD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (SGD) ACC","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU1044874839.SGD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"AGH\" (SGDHDG) ACC","LU1044876610.USD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"ZU\" (USD) ACC","SG9999002463.SGD":"LionGlobal China Growth SGD","BK1131":"金融交易所和数据","LU0048597586.USD":"富达亚洲焦点A","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1642822792.SGD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"A\" (SGD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","01244":"思路迪医药股份","LU0140636845.USD":"施罗德大中华区股票A Acc","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1044875133.USD":"天利亚洲反向股票 AU Acc","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU0211977185.USD":"EASTSPRING INVESTMENTS GREATER CHINA EQUITY \"A\" ACC","LU0577902611.USD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"A\" (USD) ACC","LU0577902298.EUR":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (EUR) ACC","LU0251144936.SGD":"Fidelity Sustainable Asia Equity A-SGD"},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1229684&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2287545465","content_text":"生物医药公司3D MEDICINES-B(01244.HK)公布招股详情，拟全球发售1,635万股，香港公开发售占一成，国际发售占九成。招股价介乎每股22.96至26.24元。每手500股计，一手入场费13,252.23元。该股今日(11月29日)起招股，下周三(12月7日)中午截止，预期将于12月15日挂牌。联席保荐人为中金及中信建投国际。公司上市引入4名基石投资者，包括徐州经开区(香港)、Harvest、TradArt Investment SP及Mobilewise，合共认购2.35亿元公司股份。如以招股价中位数24.6元计，公司上市料净集资约2.45亿元，当中约90%主要用于产品和候选药物的研发、监管备案及商业化；约10%将用于一般企业及营运资金用途。(jl/w)~阿思达克财经新闻网址: www.aastocks.com","news_type":1,"symbols_score_info":{"00388":0.9,"01244":1}},"isVote":1,"tweetType":1,"viewCount":3555,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620870046,"gmtCreate":1669690798187,"gmtModify":1676538224000,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/620870046","repostId":"2287254564","repostType":2,"repost":{"id":"2287254564","kind":"highlight","weMediaInfo":{"introduction":"凤凰网港股","home_visible":1,"media_name":"凤凰网港股","id":"1002821290","head_image":"https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817"},"pubTimestamp":1669681789,"share":"https://ttm.financial/m/news/2287254564?lang=en_US&edition=fundamental","pubTime":"2022-11-29 08:29","market":"sh","language":"zh","title":"[IPO] 3D MEDICINES-B (01244) begins its IPO today with an entry fee of HK$13,252.23.","url":"https://stock-news.laohu8.com/highlight/detail?id=2287254564","media":"凤凰网港股","summary":"3D MEDICINES-B今起招股，拟全球发售1635万股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价介乎22.96-26.24港元，每手500股，入场费13252.23港元；中金公司及中信建投国际为联席保荐人；该股份预期将于12月15日挂牌上市。据悉，3D MEDICINES是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。","content":"<p><html><body>3D MEDICINES-B (01244) begins its IPO today, planning to offer 16.35 million shares globally, of which 10% will be offered in Hong Kong, 90% will be offered internationally, and there will be an over-allotment option of 15%. The offer price per share ranges from HK$22.96 to HK$26.24, with 500 shares per lot and an entry fee of HK$13,252.23;<a href=\"https://laohu8.com/S/601995\">CICC</a>and<a href=\"https://laohu8.com/S/601066\">CITIC Securities</a>International is the joint sponsor; The shares are expected to be listed on December 15. It is reported that 3D MEDICINES is a biomedical company founded in 2014, dedicated to the development of oncology drugs for cancer patients, especially those who need long-term treatment. The company's core business model is to develop and commercialize oncology products and drug candidates through joint development, licensing, and independent discovery. A pipeline has been established that includes one core product and 11 drug candidates, with the core product Envolizumab (brand name: Envida) being the pillar product, which was approved in November 2021 and commercialized in December 2021. Seven other drug candidates are in the clinical stage. Use of funds raised: Approximately 90% will be mainly used for the research and development, regulatory filing and commercialization of the company's products and drug candidates; Approximately 10% will be used for the company's general corporate and working capital purposes.</p><p></body></html></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>[IPO] 3D MEDICINES-B (01244) begins its IPO today with an entry fee of HK$13,252.23.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n[IPO] 3D MEDICINES-B (01244) begins its IPO today with an entry fee of HK$13,252.23.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1002821290\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">凤凰网港股 </p>\n<p class=\"h-time smaller\">2022-11-29 08:29</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body>3D MEDICINES-B (01244) begins its IPO today, planning to offer 16.35 million shares globally, of which 10% will be offered in Hong Kong, 90% will be offered internationally, and there will be an over-allotment option of 15%. The offer price per share ranges from HK$22.96 to HK$26.24, with 500 shares per lot and an entry fee of HK$13,252.23;<a href=\"https://laohu8.com/S/601995\">CICC</a>and<a href=\"https://laohu8.com/S/601066\">CITIC Securities</a>International is the joint sponsor; The shares are expected to be listed on December 15. It is reported that 3D MEDICINES is a biomedical company founded in 2014, dedicated to the development of oncology drugs for cancer patients, especially those who need long-term treatment. The company's core business model is to develop and commercialize oncology products and drug candidates through joint development, licensing, and independent discovery. A pipeline has been established that includes one core product and 11 drug candidates, with the core product Envolizumab (brand name: Envida) being the pillar product, which was approved in November 2021 and commercialized in December 2021. Seven other drug candidates are in the clinical stage. Use of funds raised: Approximately 90% will be mainly used for the research and development, regulatory filing and commercialization of the company's products and drug candidates; Approximately 10% will be used for the company's general corporate and working capital purposes.</p><p></body></html></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IPO":"Renaissance IPO ETF","01244":"思路迪医药股份"},"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=62a79e0fe0fe0a2c4d3a7e8494242b53","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2287254564","content_text":"3D MEDICINES-B(01244)今起招股，拟全球发售1635万股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价介乎22.96-26.24港元，每手500股，入场费13252.23港元；中金公司及中信建投国际为联席保荐人；该股份预期将于12月15日挂牌上市。据悉，3D MEDICINES是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。公司的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名:恩维达)为支柱产品，已于2021年11月获批并于2021年12月商业化，另有7款其他候选药物处于 临床阶段。 所筹资金用途：约90%将主要用于公司产品和候选药物的研发、监管备案及商业化；约10%将用于公司的一般企业及营运资金用途。","news_type":1,"symbols_score_info":{"IPO":1,"01244":1}},"isVote":1,"tweetType":1,"viewCount":4424,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620847528,"gmtCreate":1669690625866,"gmtModify":1676538223984,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/620847528","repostId":"1107729224","repostType":2,"repost":{"id":"1107729224","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1669684496,"share":"https://ttm.financial/m/news/1107729224?lang=en_US&edition=fundamental","pubTime":"2022-11-29 09:14","market":"hk","language":"zh","title":"IPO | 3D MEDICINES-B begins IPO today, admission fee HK$13,252.23","url":"https://stock-news.laohu8.com/highlight/detail?id=1107729224","media":"老虎资讯综合","summary":"11月29日，3D MEDICINES-B发布公告，公司拟全球发售1635万股股份，其中中国香港发售股份163.5万股，国际发售股份1471.5万股，另有15%超额配股权；2022年11月29日至12","content":"<p><html><head></head><body>On November 29,<a href=\"https://laohu8.com/S/01244\">3D MEDICINES-B</a>The company announced that it plans to offer 16.35 million shares globally, including 1.635 million shares offered in Hong Kong, 14.715 million shares offered internationally, and a 15% over-allotment option. The IPO will run from November 29 to December 7, 2022, with the expected pricing date being December 7. The offer price will be HK$22.96-26.24 per offer share, with 500 shares per lot, and an admission fee of approximately HK$13,252.23; CICC and CITIC Securities International are the joint sponsors; The Shares are expected to be listed on the Main Board of the Stock Exchange on 15 December 2022.</p><p><img src=\"https://static.tigerbbs.com/2c0be958a118bf20d9cd87db8c523bd9\" tg-width=\"897\" tg-height=\"709\" width=\"100%\" height=\"auto\"/></p><p><b>Subscription ladder:</b></p><p>Each lot contains 500 shares, with an entry fee of HK$13,252.23.</p><p>The threshold for Group B is 200 million shares, and the funds required for subscription are approximately HK$5,300,891.97.</p><p><img src=\"https://static.tigerbbs.com/c92f15f2d5dc92f088705e284d6c494f\" tg-width=\"897\" tg-height=\"535\" width=\"100%\" height=\"auto\"/></p><p>The group is a biopharmaceutical company founded in 2014, dedicated to the development of oncology drugs for cancer patients, especially those who require long-term treatment. The Group's core business model is to develop and commercialize oncology products and drug candidates through joint collaborative development, licensed introduction and independent discovery. The Group plans to further enhance its internal discovery capabilities after the Listing and continue to use the collaborative development and licensing model to conduct clinical trials for more indications to benefit chronic cancer patients. As of the Latest Practicable Date, the Group had established a pipeline comprising one core product and 11 drug candidates, of which the core product was envolizumab (brand name: Envida). ® It is the Group's pillar product, which was approved in November 2021 and commercialized in December 2021. Seven other drug candidates are in the clinical stage (including drug candidates for which the Group has initiated clinical trials or has obtained IND approval and is preparing to initiate clinical trials).</p><p>The Group's core product, envolizumab, is a subcutaneous PD-L1 antibody that has been approved in China for the treatment of previously treated microsatellite highly instable (MSI-H)/mismatch repair malfunction (dMMR) advanced solid tumors. As of the Latest Practicable Date, the Group's core products were only approved for this indication. According to Frost & Sullivan, as of the Latest Practicable Date, there were four commercialization peers and five clinical-stage peers in China competing with the Core Products for the treatment of MSI-H/dMMR tumors. The Group faces fierce competition from existing products and potential drug candidates (including monoclonal and bispecific antibodies targeting PD-1/L1) in the entire oncology market. The market opportunities for its core products may be small because they target advanced treatments for most target indications. For example, the incidence of MSI-H/dMMR advanced solid tumors in China was approximately 146,100 cases in 2021, and is expected to reach approximately 186,000 cases in 2030, and only about 50% of cases will receive more than one treatment.</p><p>The Group has entered into the Cornerstone Investment Agreement, pursuant to which the Cornerstone Investors have agreed, subject to certain conditions, to subscribe for the Offer Shares at the Offer Price for an aggregate of HK$235 million. Assuming an Offer Price of HK$24.60 (i.e., the mid-point of the indicative Offer Price range set out in this prospectus), the total number of Offer Shares to be subscribed by Cornerstone Investors would be 9.5365 million Offer Shares. Cornerstone investors include Xuzhou Economic and Technological Development Zone (Hong Kong) Investment Co., Ltd., Harvest, TradArt Investment SP, and Mobilewise.</p><p><img src=\"https://static.tigerbbs.com/65b7af483bb5bb129e17cb7a66844666\" tg-width=\"894\" tg-height=\"522\" width=\"100%\" height=\"auto\"/></p><p>Assuming the over-allotment option is not exercised and the offer price is HK$24.60 per share, the Group estimates that the total net proceeds from the global offering will be approximately HK$245 million. The Group currently intends to use approximately 90% of the net proceeds it will receive from this offering primarily for the research and development, regulatory filing and commercialization of the Group's products and drug candidates; and approximately 10% will be used for general corporate and working capital purposes of the Group.</p><p></body></html></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO | 3D MEDICINES-B begins IPO today, admission fee HK$13,252.23</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO | 3D MEDICINES-B begins IPO today, admission fee HK$13,252.23\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2022-11-29 09:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>On November 29,<a href=\"https://laohu8.com/S/01244\">3D MEDICINES-B</a>The company announced that it plans to offer 16.35 million shares globally, including 1.635 million shares offered in Hong Kong, 14.715 million shares offered internationally, and a 15% over-allotment option. The IPO will run from November 29 to December 7, 2022, with the expected pricing date being December 7. The offer price will be HK$22.96-26.24 per offer share, with 500 shares per lot, and an admission fee of approximately HK$13,252.23; CICC and CITIC Securities International are the joint sponsors; The Shares are expected to be listed on the Main Board of the Stock Exchange on 15 December 2022.</p><p><img src=\"https://static.tigerbbs.com/2c0be958a118bf20d9cd87db8c523bd9\" tg-width=\"897\" tg-height=\"709\" width=\"100%\" height=\"auto\"/></p><p><b>Subscription ladder:</b></p><p>Each lot contains 500 shares, with an entry fee of HK$13,252.23.</p><p>The threshold for Group B is 200 million shares, and the funds required for subscription are approximately HK$5,300,891.97.</p><p><img src=\"https://static.tigerbbs.com/c92f15f2d5dc92f088705e284d6c494f\" tg-width=\"897\" tg-height=\"535\" width=\"100%\" height=\"auto\"/></p><p>The group is a biopharmaceutical company founded in 2014, dedicated to the development of oncology drugs for cancer patients, especially those who require long-term treatment. The Group's core business model is to develop and commercialize oncology products and drug candidates through joint collaborative development, licensed introduction and independent discovery. The Group plans to further enhance its internal discovery capabilities after the Listing and continue to use the collaborative development and licensing model to conduct clinical trials for more indications to benefit chronic cancer patients. As of the Latest Practicable Date, the Group had established a pipeline comprising one core product and 11 drug candidates, of which the core product was envolizumab (brand name: Envida). ® It is the Group's pillar product, which was approved in November 2021 and commercialized in December 2021. Seven other drug candidates are in the clinical stage (including drug candidates for which the Group has initiated clinical trials or has obtained IND approval and is preparing to initiate clinical trials).</p><p>The Group's core product, envolizumab, is a subcutaneous PD-L1 antibody that has been approved in China for the treatment of previously treated microsatellite highly instable (MSI-H)/mismatch repair malfunction (dMMR) advanced solid tumors. As of the Latest Practicable Date, the Group's core products were only approved for this indication. According to Frost & Sullivan, as of the Latest Practicable Date, there were four commercialization peers and five clinical-stage peers in China competing with the Core Products for the treatment of MSI-H/dMMR tumors. The Group faces fierce competition from existing products and potential drug candidates (including monoclonal and bispecific antibodies targeting PD-1/L1) in the entire oncology market. The market opportunities for its core products may be small because they target advanced treatments for most target indications. For example, the incidence of MSI-H/dMMR advanced solid tumors in China was approximately 146,100 cases in 2021, and is expected to reach approximately 186,000 cases in 2030, and only about 50% of cases will receive more than one treatment.</p><p>The Group has entered into the Cornerstone Investment Agreement, pursuant to which the Cornerstone Investors have agreed, subject to certain conditions, to subscribe for the Offer Shares at the Offer Price for an aggregate of HK$235 million. Assuming an Offer Price of HK$24.60 (i.e., the mid-point of the indicative Offer Price range set out in this prospectus), the total number of Offer Shares to be subscribed by Cornerstone Investors would be 9.5365 million Offer Shares. Cornerstone investors include Xuzhou Economic and Technological Development Zone (Hong Kong) Investment Co., Ltd., Harvest, TradArt Investment SP, and Mobilewise.</p><p><img src=\"https://static.tigerbbs.com/65b7af483bb5bb129e17cb7a66844666\" tg-width=\"894\" tg-height=\"522\" width=\"100%\" height=\"auto\"/></p><p>Assuming the over-allotment option is not exercised and the offer price is HK$24.60 per share, the Group estimates that the total net proceeds from the global offering will be approximately HK$245 million. The Group currently intends to use approximately 90% of the net proceeds it will receive from this offering primarily for the research and development, regulatory filing and commercialization of the Group's products and drug candidates; and approximately 10% will be used for general corporate and working capital purposes of the Group.</p><p></body></html></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/26d35a88c8d9d9d46abd395d2bd24396","relate_stocks":{"01244":"思路迪医药股份"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107729224","content_text":"11月29日，3D MEDICINES-B发布公告，公司拟全球发售1635万股股份，其中中国香港发售股份163.5万股，国际发售股份1471.5万股，另有15%超额配股权；2022年11月29日至12月7日招股，预期定价日为12月7日；发售价将为每股发售股份22.96-26.24港元，每手买卖单位500股，入场费约13252.23港元；中金公司及中信建投国际为联席保荐人；预期股份将于2022年12月15日于联交所主板挂牌上市。申购阶梯：每手500股，入场费13252.23港元。乙组门槛为200000万股，申购所需资金约5300891.97港元。集团是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。集团的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。集团计划于上市后进一步提升集团的内部发现能力及继续利用合作开发及许可引进模式开展针对更多适应症的临床试验造福慢性癌症患者。截至最后实际可行日期，集团已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名：恩维达®)为集团的支柱产品，已于2021年11月获批并于2021年12月商业化，另有七款其他候选药物处于临床阶段(包括集团已启动临床试验或已取得IND批准及正准备启动临床试验的候选药物)。集团的核心产品恩沃利单抗是一款皮下注射PD-L1抗体，其已在中国获批用于治疗既往接受过治疗的微卫星高度不稳定(MSI-H)╱错配修复功能缺陷(dMMR)晚期实体瘤。截至最后实际可行日期，集团的核心产品仅获批用于这一适应症。根据弗若斯特沙利文的资料，截至最后实际可行日期，在中国有四名商业化同行及五名临床阶段同行就治疗MSI-H/dMMR肿瘤与核心产品竞争。集团于整个肿瘤市场面临来自现有产品及潜在候选药物(包括靶向PD-1/L1的单克隆及双特异性抗体)的激烈竞争，核心产品的市场机会可能很小，因为其靶向大多数目标适应症的晚期治疗。例如，MSI-H/ dMMR晚期实体瘤在中国的发病数于2021年约为14.61万例，预期于2030年将达到约18.6万例，且仅约50%的病例将接受一次以上治疗。集团已订立基石投资协议，据此，基石投资者已同意在若干条件规限下按发售价认购以合共2.35亿港元发售股份。假设发售价为24.60港元(即本招股章程所载指示性发售价范围的中位数)，基石投资者将认购的发售股份总数为953.65万股发售股份。基石投资者包括徐州经济技术开发区(香港)投资有限公司、Harvest、TradArt Investment SP、以及Mobilewise。假设超额配股权未获行使及发售价为每股24.60港元，集团估计公司将收取的全球发售所得款项净额合计约为2.45亿港元。集团目前拟将集团将从此次发售所收取的所得款项净额约90%主要用于集团产品和候选药物的研发、监管备案及商业化；及约10%将用于集团的一般企业及营运资金用途。","news_type":1,"symbols_score_info":{"01244":0.9}},"isVote":1,"tweetType":1,"viewCount":3181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":667484132,"gmtCreate":1669088621329,"gmtModify":1676538150365,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"Woow going cool🔥😀","listText":"Woow going cool🔥😀","text":"Woow going cool🔥😀","images":[{"img":"https://static.tigerbbs.com/2f60c2d5ef40949bb95fa65ace885c5b","width":"1080","height":"2182"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/667484132","isVote":1,"tweetType":1,"viewCount":2942,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":667416640,"gmtCreate":1669083860083,"gmtModify":1676538149421,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/667416640","repostId":"667438230","repostType":1,"repost":{"id":667438230,"gmtCreate":1669079087422,"gmtModify":1676538149059,"author":{"id":"3463446769405484","authorId":"3463446769405484","name":"木讷呆滞的短线价格投机","avatar":"https://static.tigerbbs.com/baa555d394b2b85dd2592f9f5a3db2bb","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3463446769405484","idStr":"3463446769405484"},"themes":[],"title":"","htmlText":"NQ100的首位度，越來越分化了，但只要一哥二哥穩如老狗，就問題不大！","listText":"NQ100的首位度，越來越分化了，但只要一哥二哥穩如老狗，就問題不大！","text":"NQ100的首位度，越來越分化了，但只要一哥二哥穩如老狗，就問題不大！","images":[{"img":"https://static.tigerbbs.com/ff2c4b6715af8272f3ecb153cc130926","width":"1080","height":"2185"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/667438230","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":722,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":667392107,"gmtCreate":1668563173110,"gmtModify":1676538076811,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/667392107","repostId":"667947871","repostType":1,"repost":{"id":667947871,"gmtCreate":1668525289096,"gmtModify":1676538070996,"author":{"id":"3570511940076236","authorId":"3570511940076236","name":"AdaMao","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570511940076236","idStr":"3570511940076236"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/BBBY\">$3B家居(BBBY)$&nbsp;</a>想問下大家，這玩意還有救嗎？我在山頂入的，現在就剩一條破褲衩了，還有必要留着嗎？","listText":"<a href=\"https://laohu8.com/S/BBBY\">$3B家居(BBBY)$&nbsp;</a>想問下大家，這玩意還有救嗎？我在山頂入的，現在就剩一條破褲衩了，還有必要留着嗎？","text":"$3B家居(BBBY)$ 想問下大家，這玩意還有救嗎？我在山頂入的，現在就剩一條破褲衩了，還有必要留着嗎？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/667947871","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1031,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":629384276,"gmtCreate":1670270184797,"gmtModify":1676538332593,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍👍👍","listText":"👍👍👍","text":"👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/629384276","isVote":1,"tweetType":1,"viewCount":3675,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":629990197,"gmtCreate":1670182306121,"gmtModify":1676538314350,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍👍👍👍","listText":"👍👍👍👍","text":"👍👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/629990197","isVote":1,"tweetType":1,"viewCount":3554,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":629052879,"gmtCreate":1670121696592,"gmtModify":1676538306259,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/629052879","isVote":1,"tweetType":1,"viewCount":3842,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":629052153,"gmtCreate":1670121682274,"gmtModify":1676538306258,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/629052153","isVote":1,"tweetType":1,"viewCount":3640,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620879931,"gmtCreate":1669691002724,"gmtModify":1676538224047,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/620879931","repostId":"2287354144","repostType":2,"repost":{"id":"2287354144","kind":"news","pubTimestamp":1669674367,"share":"https://ttm.financial/m/news/2287354144?lang=en_US&edition=fundamental","pubTime":"2022-11-29 06:26","market":"hk","language":"zh","title":"Siludi applies to issue 16.35 million shares through Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2287354144","media":"媒体滚动","summary":"思路迪（3D Medicines）在港交所公告称，申请通过香港IPO发行1635万股股票，股票发行价指导区间为每股22.96-26.24港元，预计12月15日将开始交易。","content":"<p><html><body>3D Medicines announced on the Hong Kong Stock Exchange that it has applied to issue 16.35 million shares through a Hong Kong IPO, with a guidance price range of HK$22.96-26.24 per share. Trading is expected to begin on December 15.</p><p></body></html></p>","source":"sina_symbol","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Siludi applies to issue 16.35 million shares through Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSiludi applies to issue 16.35 million shares through Hong Kong IPO\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">媒体滚动</strong><span class=\"h-time small\">2022-11-29 06:26</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body>3D Medicines announced on the Hong Kong Stock Exchange that it has applied to issue 16.35 million shares through a Hong Kong IPO, with a guidance price range of HK$22.96-26.24 per share. Trading is expected to begin on December 15.</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-11-29/doc-imqmmthc6355254.shtml\">媒体滚动</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01244":"思路迪医药股份","IPO":"Renaissance IPO ETF"},"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-11-29/doc-imqmmthc6355254.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2287354144","content_text":"思路迪（3D Medicines）在港交所公告称，申请通过香港IPO发行1635万股股票，股票发行价指导区间为每股22.96-26.24港元，预计12月15日将开始交易。","news_type":1,"symbols_score_info":{"IPO":1,"01244":1}},"isVote":1,"tweetType":1,"viewCount":4207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620870264,"gmtCreate":1669690966159,"gmtModify":1676538224024,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/620870264","repostId":"2287453885","repostType":2,"isVote":1,"tweetType":1,"viewCount":4320,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620870130,"gmtCreate":1669690916322,"gmtModify":1676538224016,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/620870130","repostId":"2287545465","repostType":2,"repost":{"id":"2287545465","kind":"news","pubTimestamp":1669681671,"share":"https://ttm.financial/m/news/2287545465?lang=en_US&edition=fundamental","pubTime":"2022-11-29 08:27","market":"us","language":"zh","title":"IPO News: 3D MEDICINES-B (01244.HK) launches its IPO today with an entry fee of HK$13,252.23 per lot.","url":"https://stock-news.laohu8.com/highlight/detail?id=2287545465","media":"AAFN","summary":"生物医药公司3D MEDICINES-B公布招股详情，拟全球发售1,635万股，香港公开发售占一成，国际发售占九成。招股价介乎每股22.96至26.24元。每手500股计，一手入场费13,252.23元。该股今日起招股，下周三中午截止，预期将于12月15日挂牌。公司上市引入4名基石投资者，包括徐州经开区(香港)、Harvest、TradArt Investment SP及Mobilewise，合共认购2.35亿元公司股份。","content":"<p><div>Biopharmaceutical company 3D MEDICINES-B (01244.HK) announced details of its IPO, planning to offer 16.35 million shares globally, with 10% from the Hong Kong public offering and 90% from the international offering. The offer price ranged from RMB22.96 to RMB26.24 per share. Each lot consists of 500 shares, and the entry fee for each lot is 13,252.23 yuan. The stock begins its IPO today (November 29) and closes at noon next Wednesday (December 7). It is expected to be listed on December 15. The joint sponsors are CICC and CITIC Securities International. The company's IPO attracted four cornerstone investors, including Xuzhou Economic and Technological Development Zone (Hong Kong), ...</p><p><a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1229684&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web page link</a></div></p>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO News: 3D MEDICINES-B (01244.HK) launches its IPO today with an entry fee of HK$13,252.23 per lot.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO News: 3D MEDICINES-B (01244.HK) launches its IPO today with an entry fee of HK$13,252.23 per lot.\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">AAFN</strong><span class=\"h-time small\">2022-11-29 08:27</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div>Biopharmaceutical company 3D MEDICINES-B (01244.HK) announced details of its IPO, planning to offer 16.35 million shares globally, with 10% from the Hong Kong public offering and 90% from the international offering. The offer price ranged from RMB22.96 to RMB26.24 per share. Each lot consists of 500 shares, and the entry fee for each lot is 13,252.23 yuan. The stock begins its IPO today (November 29) and closes at noon next Wednesday (December 7). It is expected to be listed on December 15. The joint sponsors are CICC and CITIC Securities International. The company's IPO attracted four cornerstone investors, including Xuzhou Economic and Technological Development Zone (Hong Kong), ...</p><p><a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1229684&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web page link</a></div></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1229684&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">AAFN</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","BK1521":"挪威政府全球养老基金持仓","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0577902538.SGD":"Fullerton Lux Funds - Asia Growth and Income Equities A Acc SGD","LU0873338254.USD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (USD) INC","00388":"香港交易所","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","BK1589":"北水核心资产","LU0577902454.USD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (USD) ACC","LU0577902371.SGD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (SGD) ACC","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU1044874839.SGD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"AGH\" (SGDHDG) ACC","LU1044876610.USD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"ZU\" (USD) ACC","SG9999002463.SGD":"LionGlobal China Growth SGD","BK1131":"金融交易所和数据","LU0048597586.USD":"富达亚洲焦点A","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1642822792.SGD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"A\" (SGD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","01244":"思路迪医药股份","LU0140636845.USD":"施罗德大中华区股票A Acc","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1044875133.USD":"天利亚洲反向股票 AU Acc","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU0211977185.USD":"EASTSPRING INVESTMENTS GREATER CHINA EQUITY \"A\" ACC","LU0577902611.USD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"A\" (USD) ACC","LU0577902298.EUR":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (EUR) ACC","LU0251144936.SGD":"Fidelity Sustainable Asia Equity A-SGD"},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1229684&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2287545465","content_text":"生物医药公司3D MEDICINES-B(01244.HK)公布招股详情，拟全球发售1,635万股，香港公开发售占一成，国际发售占九成。招股价介乎每股22.96至26.24元。每手500股计，一手入场费13,252.23元。该股今日(11月29日)起招股，下周三(12月7日)中午截止，预期将于12月15日挂牌。联席保荐人为中金及中信建投国际。公司上市引入4名基石投资者，包括徐州经开区(香港)、Harvest、TradArt Investment SP及Mobilewise，合共认购2.35亿元公司股份。如以招股价中位数24.6元计，公司上市料净集资约2.45亿元，当中约90%主要用于产品和候选药物的研发、监管备案及商业化；约10%将用于一般企业及营运资金用途。(jl/w)~阿思达克财经新闻网址: www.aastocks.com","news_type":1,"symbols_score_info":{"00388":0.9,"01244":1}},"isVote":1,"tweetType":1,"viewCount":3555,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620870046,"gmtCreate":1669690798187,"gmtModify":1676538224000,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/620870046","repostId":"2287254564","repostType":2,"repost":{"id":"2287254564","kind":"highlight","weMediaInfo":{"introduction":"凤凰网港股","home_visible":1,"media_name":"凤凰网港股","id":"1002821290","head_image":"https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817"},"pubTimestamp":1669681789,"share":"https://ttm.financial/m/news/2287254564?lang=en_US&edition=fundamental","pubTime":"2022-11-29 08:29","market":"sh","language":"zh","title":"[IPO] 3D MEDICINES-B (01244) begins its IPO today with an entry fee of HK$13,252.23.","url":"https://stock-news.laohu8.com/highlight/detail?id=2287254564","media":"凤凰网港股","summary":"3D MEDICINES-B今起招股，拟全球发售1635万股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价介乎22.96-26.24港元，每手500股，入场费13252.23港元；中金公司及中信建投国际为联席保荐人；该股份预期将于12月15日挂牌上市。据悉，3D MEDICINES是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。","content":"<p><html><body>3D MEDICINES-B (01244) begins its IPO today, planning to offer 16.35 million shares globally, of which 10% will be offered in Hong Kong, 90% will be offered internationally, and there will be an over-allotment option of 15%. The offer price per share ranges from HK$22.96 to HK$26.24, with 500 shares per lot and an entry fee of HK$13,252.23;<a href=\"https://laohu8.com/S/601995\">CICC</a>and<a href=\"https://laohu8.com/S/601066\">CITIC Securities</a>International is the joint sponsor; The shares are expected to be listed on December 15. It is reported that 3D MEDICINES is a biomedical company founded in 2014, dedicated to the development of oncology drugs for cancer patients, especially those who need long-term treatment. The company's core business model is to develop and commercialize oncology products and drug candidates through joint development, licensing, and independent discovery. A pipeline has been established that includes one core product and 11 drug candidates, with the core product Envolizumab (brand name: Envida) being the pillar product, which was approved in November 2021 and commercialized in December 2021. Seven other drug candidates are in the clinical stage. Use of funds raised: Approximately 90% will be mainly used for the research and development, regulatory filing and commercialization of the company's products and drug candidates; Approximately 10% will be used for the company's general corporate and working capital purposes.</p><p></body></html></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>[IPO] 3D MEDICINES-B (01244) begins its IPO today with an entry fee of HK$13,252.23.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n[IPO] 3D MEDICINES-B (01244) begins its IPO today with an entry fee of HK$13,252.23.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1002821290\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">凤凰网港股 </p>\n<p class=\"h-time smaller\">2022-11-29 08:29</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body>3D MEDICINES-B (01244) begins its IPO today, planning to offer 16.35 million shares globally, of which 10% will be offered in Hong Kong, 90% will be offered internationally, and there will be an over-allotment option of 15%. The offer price per share ranges from HK$22.96 to HK$26.24, with 500 shares per lot and an entry fee of HK$13,252.23;<a href=\"https://laohu8.com/S/601995\">CICC</a>and<a href=\"https://laohu8.com/S/601066\">CITIC Securities</a>International is the joint sponsor; The shares are expected to be listed on December 15. It is reported that 3D MEDICINES is a biomedical company founded in 2014, dedicated to the development of oncology drugs for cancer patients, especially those who need long-term treatment. The company's core business model is to develop and commercialize oncology products and drug candidates through joint development, licensing, and independent discovery. A pipeline has been established that includes one core product and 11 drug candidates, with the core product Envolizumab (brand name: Envida) being the pillar product, which was approved in November 2021 and commercialized in December 2021. Seven other drug candidates are in the clinical stage. Use of funds raised: Approximately 90% will be mainly used for the research and development, regulatory filing and commercialization of the company's products and drug candidates; Approximately 10% will be used for the company's general corporate and working capital purposes.</p><p></body></html></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IPO":"Renaissance IPO ETF","01244":"思路迪医药股份"},"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=62a79e0fe0fe0a2c4d3a7e8494242b53","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2287254564","content_text":"3D MEDICINES-B(01244)今起招股，拟全球发售1635万股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价介乎22.96-26.24港元，每手500股，入场费13252.23港元；中金公司及中信建投国际为联席保荐人；该股份预期将于12月15日挂牌上市。据悉，3D MEDICINES是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。公司的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名:恩维达)为支柱产品，已于2021年11月获批并于2021年12月商业化，另有7款其他候选药物处于 临床阶段。 所筹资金用途：约90%将主要用于公司产品和候选药物的研发、监管备案及商业化；约10%将用于公司的一般企业及营运资金用途。","news_type":1,"symbols_score_info":{"IPO":1,"01244":1}},"isVote":1,"tweetType":1,"viewCount":4424,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620847528,"gmtCreate":1669690625866,"gmtModify":1676538223984,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/620847528","repostId":"1107729224","repostType":2,"repost":{"id":"1107729224","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1669684496,"share":"https://ttm.financial/m/news/1107729224?lang=en_US&edition=fundamental","pubTime":"2022-11-29 09:14","market":"hk","language":"zh","title":"IPO | 3D MEDICINES-B begins IPO today, admission fee HK$13,252.23","url":"https://stock-news.laohu8.com/highlight/detail?id=1107729224","media":"老虎资讯综合","summary":"11月29日，3D MEDICINES-B发布公告，公司拟全球发售1635万股股份，其中中国香港发售股份163.5万股，国际发售股份1471.5万股，另有15%超额配股权；2022年11月29日至12","content":"<p><html><head></head><body>On November 29,<a href=\"https://laohu8.com/S/01244\">3D MEDICINES-B</a>The company announced that it plans to offer 16.35 million shares globally, including 1.635 million shares offered in Hong Kong, 14.715 million shares offered internationally, and a 15% over-allotment option. The IPO will run from November 29 to December 7, 2022, with the expected pricing date being December 7. The offer price will be HK$22.96-26.24 per offer share, with 500 shares per lot, and an admission fee of approximately HK$13,252.23; CICC and CITIC Securities International are the joint sponsors; The Shares are expected to be listed on the Main Board of the Stock Exchange on 15 December 2022.</p><p><img src=\"https://static.tigerbbs.com/2c0be958a118bf20d9cd87db8c523bd9\" tg-width=\"897\" tg-height=\"709\" width=\"100%\" height=\"auto\"/></p><p><b>Subscription ladder:</b></p><p>Each lot contains 500 shares, with an entry fee of HK$13,252.23.</p><p>The threshold for Group B is 200 million shares, and the funds required for subscription are approximately HK$5,300,891.97.</p><p><img src=\"https://static.tigerbbs.com/c92f15f2d5dc92f088705e284d6c494f\" tg-width=\"897\" tg-height=\"535\" width=\"100%\" height=\"auto\"/></p><p>The group is a biopharmaceutical company founded in 2014, dedicated to the development of oncology drugs for cancer patients, especially those who require long-term treatment. The Group's core business model is to develop and commercialize oncology products and drug candidates through joint collaborative development, licensed introduction and independent discovery. The Group plans to further enhance its internal discovery capabilities after the Listing and continue to use the collaborative development and licensing model to conduct clinical trials for more indications to benefit chronic cancer patients. As of the Latest Practicable Date, the Group had established a pipeline comprising one core product and 11 drug candidates, of which the core product was envolizumab (brand name: Envida). ® It is the Group's pillar product, which was approved in November 2021 and commercialized in December 2021. Seven other drug candidates are in the clinical stage (including drug candidates for which the Group has initiated clinical trials or has obtained IND approval and is preparing to initiate clinical trials).</p><p>The Group's core product, envolizumab, is a subcutaneous PD-L1 antibody that has been approved in China for the treatment of previously treated microsatellite highly instable (MSI-H)/mismatch repair malfunction (dMMR) advanced solid tumors. As of the Latest Practicable Date, the Group's core products were only approved for this indication. According to Frost & Sullivan, as of the Latest Practicable Date, there were four commercialization peers and five clinical-stage peers in China competing with the Core Products for the treatment of MSI-H/dMMR tumors. The Group faces fierce competition from existing products and potential drug candidates (including monoclonal and bispecific antibodies targeting PD-1/L1) in the entire oncology market. The market opportunities for its core products may be small because they target advanced treatments for most target indications. For example, the incidence of MSI-H/dMMR advanced solid tumors in China was approximately 146,100 cases in 2021, and is expected to reach approximately 186,000 cases in 2030, and only about 50% of cases will receive more than one treatment.</p><p>The Group has entered into the Cornerstone Investment Agreement, pursuant to which the Cornerstone Investors have agreed, subject to certain conditions, to subscribe for the Offer Shares at the Offer Price for an aggregate of HK$235 million. Assuming an Offer Price of HK$24.60 (i.e., the mid-point of the indicative Offer Price range set out in this prospectus), the total number of Offer Shares to be subscribed by Cornerstone Investors would be 9.5365 million Offer Shares. Cornerstone investors include Xuzhou Economic and Technological Development Zone (Hong Kong) Investment Co., Ltd., Harvest, TradArt Investment SP, and Mobilewise.</p><p><img src=\"https://static.tigerbbs.com/65b7af483bb5bb129e17cb7a66844666\" tg-width=\"894\" tg-height=\"522\" width=\"100%\" height=\"auto\"/></p><p>Assuming the over-allotment option is not exercised and the offer price is HK$24.60 per share, the Group estimates that the total net proceeds from the global offering will be approximately HK$245 million. The Group currently intends to use approximately 90% of the net proceeds it will receive from this offering primarily for the research and development, regulatory filing and commercialization of the Group's products and drug candidates; and approximately 10% will be used for general corporate and working capital purposes of the Group.</p><p></body></html></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO | 3D MEDICINES-B begins IPO today, admission fee HK$13,252.23</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO | 3D MEDICINES-B begins IPO today, admission fee HK$13,252.23\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2022-11-29 09:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>On November 29,<a href=\"https://laohu8.com/S/01244\">3D MEDICINES-B</a>The company announced that it plans to offer 16.35 million shares globally, including 1.635 million shares offered in Hong Kong, 14.715 million shares offered internationally, and a 15% over-allotment option. The IPO will run from November 29 to December 7, 2022, with the expected pricing date being December 7. The offer price will be HK$22.96-26.24 per offer share, with 500 shares per lot, and an admission fee of approximately HK$13,252.23; CICC and CITIC Securities International are the joint sponsors; The Shares are expected to be listed on the Main Board of the Stock Exchange on 15 December 2022.</p><p><img src=\"https://static.tigerbbs.com/2c0be958a118bf20d9cd87db8c523bd9\" tg-width=\"897\" tg-height=\"709\" width=\"100%\" height=\"auto\"/></p><p><b>Subscription ladder:</b></p><p>Each lot contains 500 shares, with an entry fee of HK$13,252.23.</p><p>The threshold for Group B is 200 million shares, and the funds required for subscription are approximately HK$5,300,891.97.</p><p><img src=\"https://static.tigerbbs.com/c92f15f2d5dc92f088705e284d6c494f\" tg-width=\"897\" tg-height=\"535\" width=\"100%\" height=\"auto\"/></p><p>The group is a biopharmaceutical company founded in 2014, dedicated to the development of oncology drugs for cancer patients, especially those who require long-term treatment. The Group's core business model is to develop and commercialize oncology products and drug candidates through joint collaborative development, licensed introduction and independent discovery. The Group plans to further enhance its internal discovery capabilities after the Listing and continue to use the collaborative development and licensing model to conduct clinical trials for more indications to benefit chronic cancer patients. As of the Latest Practicable Date, the Group had established a pipeline comprising one core product and 11 drug candidates, of which the core product was envolizumab (brand name: Envida). ® It is the Group's pillar product, which was approved in November 2021 and commercialized in December 2021. Seven other drug candidates are in the clinical stage (including drug candidates for which the Group has initiated clinical trials or has obtained IND approval and is preparing to initiate clinical trials).</p><p>The Group's core product, envolizumab, is a subcutaneous PD-L1 antibody that has been approved in China for the treatment of previously treated microsatellite highly instable (MSI-H)/mismatch repair malfunction (dMMR) advanced solid tumors. As of the Latest Practicable Date, the Group's core products were only approved for this indication. According to Frost & Sullivan, as of the Latest Practicable Date, there were four commercialization peers and five clinical-stage peers in China competing with the Core Products for the treatment of MSI-H/dMMR tumors. The Group faces fierce competition from existing products and potential drug candidates (including monoclonal and bispecific antibodies targeting PD-1/L1) in the entire oncology market. The market opportunities for its core products may be small because they target advanced treatments for most target indications. For example, the incidence of MSI-H/dMMR advanced solid tumors in China was approximately 146,100 cases in 2021, and is expected to reach approximately 186,000 cases in 2030, and only about 50% of cases will receive more than one treatment.</p><p>The Group has entered into the Cornerstone Investment Agreement, pursuant to which the Cornerstone Investors have agreed, subject to certain conditions, to subscribe for the Offer Shares at the Offer Price for an aggregate of HK$235 million. Assuming an Offer Price of HK$24.60 (i.e., the mid-point of the indicative Offer Price range set out in this prospectus), the total number of Offer Shares to be subscribed by Cornerstone Investors would be 9.5365 million Offer Shares. Cornerstone investors include Xuzhou Economic and Technological Development Zone (Hong Kong) Investment Co., Ltd., Harvest, TradArt Investment SP, and Mobilewise.</p><p><img src=\"https://static.tigerbbs.com/65b7af483bb5bb129e17cb7a66844666\" tg-width=\"894\" tg-height=\"522\" width=\"100%\" height=\"auto\"/></p><p>Assuming the over-allotment option is not exercised and the offer price is HK$24.60 per share, the Group estimates that the total net proceeds from the global offering will be approximately HK$245 million. The Group currently intends to use approximately 90% of the net proceeds it will receive from this offering primarily for the research and development, regulatory filing and commercialization of the Group's products and drug candidates; and approximately 10% will be used for general corporate and working capital purposes of the Group.</p><p></body></html></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/26d35a88c8d9d9d46abd395d2bd24396","relate_stocks":{"01244":"思路迪医药股份"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107729224","content_text":"11月29日，3D MEDICINES-B发布公告，公司拟全球发售1635万股股份，其中中国香港发售股份163.5万股，国际发售股份1471.5万股，另有15%超额配股权；2022年11月29日至12月7日招股，预期定价日为12月7日；发售价将为每股发售股份22.96-26.24港元，每手买卖单位500股，入场费约13252.23港元；中金公司及中信建投国际为联席保荐人；预期股份将于2022年12月15日于联交所主板挂牌上市。申购阶梯：每手500股，入场费13252.23港元。乙组门槛为200000万股，申购所需资金约5300891.97港元。集团是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。集团的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。集团计划于上市后进一步提升集团的内部发现能力及继续利用合作开发及许可引进模式开展针对更多适应症的临床试验造福慢性癌症患者。截至最后实际可行日期，集团已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名：恩维达®)为集团的支柱产品，已于2021年11月获批并于2021年12月商业化，另有七款其他候选药物处于临床阶段(包括集团已启动临床试验或已取得IND批准及正准备启动临床试验的候选药物)。集团的核心产品恩沃利单抗是一款皮下注射PD-L1抗体，其已在中国获批用于治疗既往接受过治疗的微卫星高度不稳定(MSI-H)╱错配修复功能缺陷(dMMR)晚期实体瘤。截至最后实际可行日期，集团的核心产品仅获批用于这一适应症。根据弗若斯特沙利文的资料，截至最后实际可行日期，在中国有四名商业化同行及五名临床阶段同行就治疗MSI-H/dMMR肿瘤与核心产品竞争。集团于整个肿瘤市场面临来自现有产品及潜在候选药物(包括靶向PD-1/L1的单克隆及双特异性抗体)的激烈竞争，核心产品的市场机会可能很小，因为其靶向大多数目标适应症的晚期治疗。例如，MSI-H/ dMMR晚期实体瘤在中国的发病数于2021年约为14.61万例，预期于2030年将达到约18.6万例，且仅约50%的病例将接受一次以上治疗。集团已订立基石投资协议，据此，基石投资者已同意在若干条件规限下按发售价认购以合共2.35亿港元发售股份。假设发售价为24.60港元(即本招股章程所载指示性发售价范围的中位数)，基石投资者将认购的发售股份总数为953.65万股发售股份。基石投资者包括徐州经济技术开发区(香港)投资有限公司、Harvest、TradArt Investment SP、以及Mobilewise。假设超额配股权未获行使及发售价为每股24.60港元，集团估计公司将收取的全球发售所得款项净额合计约为2.45亿港元。集团目前拟将集团将从此次发售所收取的所得款项净额约90%主要用于集团产品和候选药物的研发、监管备案及商业化；及约10%将用于集团的一般企业及营运资金用途。","news_type":1,"symbols_score_info":{"01244":0.9}},"isVote":1,"tweetType":1,"viewCount":3181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":667484132,"gmtCreate":1669088621329,"gmtModify":1676538150365,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"title":"","htmlText":"Woow going cool🔥😀","listText":"Woow going cool🔥😀","text":"Woow going cool🔥😀","images":[{"img":"https://static.tigerbbs.com/2f60c2d5ef40949bb95fa65ace885c5b","width":"1080","height":"2182"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/667484132","isVote":1,"tweetType":1,"viewCount":2942,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}